148 related articles for article (PubMed ID: 34627594)
1. Inhibition of the CD47-SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome.
Stadler R
Lancet Haematol; 2021 Nov; 8(11):e779-e781. PubMed ID: 34627594
[No Abstract] [Full Text] [Related]
2. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
3. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
[TBL] [Abstract][Full Text] [Related]
4. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
Xiao A; Akilov OE
Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
[TBL] [Abstract][Full Text] [Related]
6. Patch tests in Sézary syndrome and mycosis fungoides.
Shupp DL; Winkelmann RK
Contact Dermatitis; 1985 Sep; 13(3):180-5. PubMed ID: 4053598
[TBL] [Abstract][Full Text] [Related]
7. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
[No Abstract] [Full Text] [Related]
9. Targeting CD47 in Sézary syndrome with SIRPαFc.
Johnson LDS; Banerjee S; Kruglov O; Viller NN; Horwitz SM; Lesokhin A; Zain J; Querfeld C; Chen R; Okada C; Sawas A; O'Connor OA; Sievers EL; Shou Y; Uger RA; Wong M; Akilov OE
Blood Adv; 2019 Apr; 3(7):1145-1153. PubMed ID: 30962222
[TBL] [Abstract][Full Text] [Related]
10. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
11. Locomotion of T cells from patients with cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides).
Gupta S; Safai B; Edelson R; Parrott D; Good R
Cell Immunol; 1980 Mar; 50(1):195-201. PubMed ID: 6967357
[No Abstract] [Full Text] [Related]
12. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
13. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
15. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
[TBL] [Abstract][Full Text] [Related]
16. The Sézary cell in the blood of patients with mycosis fungoides.
Winkelmann RK; Hoagland HC
Dermatologica; 1980; 160(2):73-9. PubMed ID: 6965373
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-cell lymphoma and atopy: is there an association?
Mehrany K; El-Azhary RA; Bouwhuis SA; Pittelkow MR
Br J Dermatol; 2003 Nov; 149(5):1013-7. PubMed ID: 14632807
[TBL] [Abstract][Full Text] [Related]
19. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
20. More about the T-cell receptor V beta repertoire usage in mycosis fungoides/Sézary syndrome.
Bachelez H; Gorochov G
Br J Dermatol; 1995 Jun; 132(6):1017-8. PubMed ID: 7662555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
